Lung Adenocarcinoma Treatment Market Size, Share & Trends Analysis Report By Treatment (Chemotherapy, Immunotherapy), By End-use (Hospitals, Specialty Clinics), By Region, And Segment Forecasts, 2024 - 2030

Market Size & Trends

The global lung adenocarcinoma treatment market size was estimated at USD 5.51 billion in 2023 and is projected to grow at a CAGR of 10.68% from 2024 to 2030. The market is driven by several key factors, including the rising incidence of lung cancer, advancements in targeted therapies and immunotherapies, increased awareness and screening programs, and the growing investment in R&D. These drivers play a significant role in shaping the landscape of treatment options available for patients suffering from this specific type of lung cancer.

According to WHO, the two most prevalent types of lung cancer are non-small cell lung carcinoma (NSCLC) and small cell lung carcinoma (SCLC). Lung adenocarcinoma is a subtype of non-small cell lung cancer (NSCLC) that develops from the epithelial cells in the lungs.

One of the primary drivers of the market is the increasing incidence of lung cancer globally. According to the Lung Cancer Research Foundation, it was estimated that 238,340 individuals in the U.S. underwent a lung cancer diagnosis in 2023. Throughout their lifetime, 1 in 16 people were diagnosed with lung cancer, including 1 in 16 men and 1 in 17 women.

The rise in smoking rates in certain regions, along with environmental factors such as air pollution and occupational hazards, has contributed to this upward trend. As more individuals are diagnosed with lung adenocarcinoma, there is a corresponding demand for effective treatment options.

Developing new and effective treatments, particularly targeted therapies and immunotherapies, is a key driver of the market growth. There was a shift observed toward these therapies, which were shown to improve patient outcomes and had fewer side effects than traditional chemotherapy. Targeted therapies, such as tyrosine kinase inhibitors (TKIs) and monoclonal antibodies (mAbs), are designed to target specific molecules involved in the growth and spread of cancer cells. These therapies were proven effective in treating NSCLC and became a standard of care for some patients with advanced NSCLC.

Market Concentration & Characteristics

The market is highly innovative, driven by advancements in targeted therapies and immunotherapies. For instance, in March 2024, Bristol Myers Squibb (BMS) reported that its Phase III KRYSTAL-12 clinical trial evaluating KRAZATI (adagrasib) for patients with NSCLC harboring KRASG12C mutations has successfully achieved its primary objectives. In addition, integrating nanotechnology into drug delivery systems is revolutionizing treatment approaches by enhancing the efficacy and reducing the side effects of existing therapies.

The level of merger and acquisition (M&A) activities in the market is medium, reflecting a strategic consolidation trend among pharmaceutical companies seeking to enhance their oncology portfolios. For instance, in March 2022, Bristol Myers Squibb acquired Turning Point Therapeutics, enhancing its oncology portfolio with repotrectinib, a promising next-generation ROS1/NTRK inhibitor aimed at treating patients with ROS1-positive non-small cell lung cancer.

The impact of regulations on the market is high, as regulatory bodies such as the FDA and EMA play a crucial role in determining which therapies gain market access. The expedited approval pathways established under initiatives, including Breakthrough Therapy Designation, facilitated faster access to innovative treatments for patients with unmet medical needs. For instance, in June 2024, AstraZeneca obtained approval in Japan for the use of Tagrisso (osimertinib) in conjunction with pemetrexed and platinum-based chemotherapy as an initial treatment option for adult patients diagnosed with locally advanced or metastatic non-small cell lung cancer (NSCLC) that is characterized by mutations in the epidermal growth factor receptor (EGFR), specifically those involving exon 19 deletions or the L858R mutation found in exon 21.

Product expansion in the market is assessed as high, driven by the continuous introduction of novel therapies and treatment combinations. The emergence of new targeted therapies, such as ALK inhibitors and PD-1/PD-L1 inhibitors, has significantly broadened the treatment options available for patients. In addition, the development of combination therapies that integrate traditional chemotherapy with novel agents is gaining traction. Immunotherapy and chemotherapy showed improved survival rates in clinical trials, leading to a shift in treatment paradigms.

Region expansion in the market is medium, with pharmaceutical companies increasingly targeting emerging markets alongside established regions such as North America and Europe. The APAC region became a focal point due to its large patient population and rising healthcare expenditures; China is witnessing rapid growth in oncology drug approvals driven by government initiatives to improve cancer care access. Several global pharmaceutical firms partnered with local companies to facilitate market entry and distribution within these regions.

Treatment Insights

The chemotherapy segment represented the largest revenue share of 36.84% in 2023. This is primarily driven by its established role in managing lung cancer and ongoing advancements in treatment regimens. Chemotherapy remains a cornerstone treatment approach, particularly for non-small cell lung cancer (NSCLC). Innovations in chemotherapy include developing new drug combinations, less toxic formulations, improved treatment efficacy, and patient tolerability. In addition, chemotherapy is considered a cost-effective option, making it accessible to a broader patient population, especially in resource-limited settings.

The immunotherapy segment is anticipated to experience the fastest-growing CAGR of 13.5% over the forecast period. The increasing prevalence of lung adenocarcinoma, a subtype of NSCLC, led to a heightened demand for innovative treatment options that offer improved efficacy and safety profiles compared to traditional therapies such as chemotherapy and radiation. Immunotherapies, such as immune checkpoint inhibitors (e.g., pembrolizumab and nivolumab), showed remarkable success in enhancing the body’s immune response against cancer cells, leading to prolonged survival rates and better quality of life for patients.

End-use Insights

Hospitals account for the largest revenue share of 64.34% in 2023, primarily due to their comprehensive infrastructure and capacity to provide a wide range of advanced cancer treatments. Hospitals are equipped to offer multidisciplinary care, including surgery, chemotherapy, radiation therapy, targeted therapies, and immunotherapies, which are essential for managing complex cases of lung adenocarcinoma. According to the National Center for Biotechnology Information (NCBI), the rising patient admissions for lung cancer treatment are driven by increasing incidence rates; approximately 609,820 new lung cancer cases were reported in the U.S. alone in 2023, which further fuels this segment’s growth. 

The specialty clinics segment is anticipated to experience the fastest CAGR over the forecast period. This growth is driven by the increasing demand for personalized and targeted therapies and the rise in patient awareness regarding lung cancer treatment options. Specialty clinics often focus on specific cancer types, providing tailored treatment plans incorporating the latest therapy advancements, including immunotherapy and targeted treatments. The clinics specializing in lung cancer are increasingly adopting innovative approaches such as liquid biopsies, which further facilitate early detection and monitoring of treatment response.

Regional Insights

The lung adenocarcinoma treatment market in North America is characterized by a strong focus on innovation and the introduction of novel therapies. The increasing prevalence of lung cancer, particularly adenocarcinoma, has prompted healthcare providers to adopt more tailored treatment approaches that consider the genetic makeup of tumors. Introducing novel therapies such as immune checkpoint inhibitors and targeted agents such as EGFR inhibitors has revolutionized treatment protocols. In addition, the market is witnessing increased mergers and acquisitions among pharmaceutical companies to expand their product portfolios and enhance research capabilities.

U.S. Lung Adenocarcinoma Treatment Market Trends

The lung adenocarcinoma treatment market in the U.S. is characterized by rapid innovation and a competitive landscape marked by strategic mergers and acquisitions among pharmaceutical companies. The approvals of new drugs expanded treatment options significantly; for instance, the FDA’s accelerated approval pathways have facilitated quicker access to promising therapies for patients with advanced disease stages. For instance, in March 2022, the FDA approved Opdivo (nivolumab) in combination with chemotherapy as a neoadjuvant treatment for certain adult patients with resectable NSCLC.

Europe Lung Adenocarcinoma Treatment Market Trends

The lung adenocarcinoma treatment market in Europe is seeing substantial growth driven by increasing lung cancer incidence and advancements in treatment options. Innovative therapies, including targeted treatments and immunotherapies, are gaining traction, with recent approvals such as Opdivo in combination with chemotherapy for neoadjuvant treatment of NSCLC marking a notable advancement. In addition, increased government funding and support for cancer research are fostering the development of new therapies and enhancing patient access to cutting-edge treatments.

The lung adenocarcinoma treatment market in the UK is described by a strong focus on precision medicine and ingenious treatment approaches. With a high prevalence of lung cancer, the UK is implementing strategies to improve early detection and treatment outcomes, including the use of advanced diagnostic tools and targeted therapies. The National Health Service (NHS) is actively promoting the adoption of personalized treatment plans based on genetic profiling, which is expected to enhance the effectiveness of therapies.

The lung adenocarcinoma treatment market in France is marked by robust government support for research and development initiatives to combat cancer. The French National Cancer Institute is pivotal in funding innovative projects exploring new therapeutic avenues, including immunotherapy and gene therapy approaches tailored for lung adenocarcinoma patients. Furthermore, France saw an uptick in clinical trials investigating novel combinations of existing treatments alongside emerging therapies. A unique aspect of this market is the country’s commitment to integrating patient perspectives into clinical decision-making processes; this approach aims to ensure that treatment plans align with patient preferences and quality-of-life considerations.

Asia Pacific Lung Adenocarcinoma Treatment Market Trends

The lung adenocarcinoma treatment market in the Asia Pacific region is witnessing significant growth driven by an increase in the prevalence of lung cancer, particularly among non-smokers. Innovative therapies such as targeted and immunotherapies gained traction, with drugs such as osimertinib and nivolumab leading the charge. The rise of personalized medicine is also a notable trend as genetic profiling becomes more accessible, allowing for tailored treatment plans that improve patient outcomes. Regulatory agencies in countries including Australia and South Korea are also streamlining approval processes for new treatments, which is expected to accelerate market entry.

The lung adenocarcinoma treatment market in Japan is witnessing significant growth. A strong emphasis on advanced therapeutic options and high healthcare standards characterizes the lung adenocarcinoma treatment market in Japan. The Japanese government implemented favorable regulatory pathways that encourage the development of new drugs, particularly those targeting specific biomarkers like EGFR mutations. For instance, in March 2023, ONO secured additional approval for Opdivo in combination with chemotherapy as a neoadjuvant treatment for NSCLC in Japan. Furthermore, Japan’s aging population presents unique challenges and opportunities; as older adults are more susceptible to lung cancer, there is an urgent need for effective treatments tailored to this demographic. 

The lung adenocarcinoma treatment market in China is fueled by a high incidence of lung cancer and a growing focus on innovative therapies. Recent regulatory approvals for targeted therapies, such as ALK inhibitors and immunotherapies, enhance patient treatment options. Additionally, the increasing prevalence of smoking and environmental pollution contributes to the rising lung cancer burden. The Chinese market is also seeing a rise in mergers and acquisitions among pharmaceutical companies to expand their product portfolios and enhance research capabilities to meet the growing demand for effective lung cancer treatments.

Latin America Lung Adenocarcinoma Treatment Market Trends

The lung adenocarcinoma treatment market in Latin America is characterized by a growing focus on improving treatment access and presenting innovative therapies. The region saw an increase in the adoption of targeted therapies and immunotherapies, which are becoming integral to treatment protocols for lung cancer. Additionally, the rising prevalence of lung cancer and the need for effective treatment options are driving investments in research and development, leading to the launch of new therapies tailored to the specific needs of the Latin American population.

The lung adenocarcinoma treatment market in Brazil region is witnessing significant growth. A combination of high incidence rates of lung cancer and significant disparities in access to care influences the lung adenocarcinoma treatment market in Brazil. The increasing prevalence of lung cancer, particularly adenocarcinoma, stimulated healthcare providers to adopt innovative treatment modalities such as immunotherapy and molecularly targeted agents. The Brazilian healthcare system faces challenges such as late diagnoses and inequitable access to advanced therapies, particularly between the public and private sectors. Recent initiatives aimed at improving tobacco control and increasing public awareness about lung cancer are expected to enhance early detection and treatment outcomes. 

Middle East & Africa Lung Adenocarcinoma Treatment Market Trends

The lung adenocarcinoma treatment market in the Middle East and Africa is witnessing significant growth driven by an increase in lung cancer incidence, particularly due to rising smoking rates and environmental factors. According to the Tobacco Atlas, Lebanon held the highest smoking rate in the Middle East, with each person smoking an average of 1,955 cigarettes in 2022. The region saw a surge in innovative therapies, including targeted therapies and immunotherapies, which have transformed treatment paradigms. The regulatory environment is evolving, with several countries streamlining approval processes for new therapies, accelerating patient access to cutting-edge treatments.

The lung adenocarcinoma treatment market in Saudi Arabia is characterized by rapid advancements in healthcare infrastructure and increased investment in oncology research. The government’s Vision 2030 initiative aims to enhance healthcare services and promote medical innovation, which led to collaborations between public health institutions and pharmaceutical companies. Furthermore, awareness campaigns about lung cancer risks are contributing to earlier diagnosis and treatment initiation, which is crucial given that early-stage lung adenocarcinoma can significantly improve survival rates. 

Key Lung Adenocarcinoma Treatment Company Insights

The market is dominated by several major pharmaceutical companies that collectively account for a significant market share. These leading players established themselves through extensive research and development efforts, resulting in the introduction of innovative targeted therapies and immunotherapies. They also expanded their product portfolios through strategic collaborations, mergers, and acquisitions. 

Recent Developments

• In April 2024, the FDA approved alectinib (Alecensa) as an adjuvant for patients diagnosed with anaplastic lymphoma kinase (ALK) - positive NSCLC after tumor resection. An FDA-sanctioned test confirmed the condition.

• In March 2024, Pfizer Inc. released long-term follow-up results from the Phase 3 CROWN trial, which evaluated the efficacy of LORBRENA (lorlatinib), a third-generation ALK inhibitor, compared to XALKORI (crizotinib) in patients with untreated, anaplastic lymphoma kinase (ALK)-positive advanced NSCLC. 

Lung Adenocarcinoma Treatment Market Report Scope

Global Lung Adenocarcinoma Treatment Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global Lung adenocarcinoma treatment market report based on treatment, end-use, and region:

• Treatment Outlook (Revenue, USD Million, 2018 - 2030)

  • Chemotherapy

  • Targeted Therapy

  • Immunotherapy

  • Radiation Therapy

  • Other

• End-use Outlook (Revenue, USD Million, 2018 - 2030)

  • Hospitals

  • Specialty Clinics

  • Other

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • Germany

    • UK

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • China

    • Japan

    • India

    • South Korea

    • Australia

    • Thailand

  • Latin America

    • Brazil

    • Argentina

  • Middle East and Africa (MEA)

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait